 | Up a level |
McClung, Michael R; O'Donoghue, Michelle L; Papapoulos, Socrates E; Bone, Henry; Langdahl, Bente; Saag, Kenneth G; Reid, Ian R; Kiel, Douglas P; Cavallari, Ilaria; Bonaca, Marc P; Wiviott, Stephen D; de Villiers, Tobias; Ling, Xu; Lippuner, Kurt; Nakamura, Toshitaka; Reginster, Jean-Yves; Rodriguez-Portales, Jose Adolfo; Roux, Christian; Zanchetta, José; Zerbini, Cristiano A F; ... (2019). Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. The lancet. Diabetes & endocrinology, 7(12), pp. 899-911. Elsevier 10.1016/S2213-8587(19)30346-8
Boonen, Steven; Reginster, Jean-Yves; Kaufman, Jean-Marc; Lippuner, Kurt; Zanchetta, Jose; Langdahl, Bente; Rizzoli, Rene; Lipschitz, Stanley; Dimai, Hans Peter; Witvrouw, Richard; Eriksen, Erik; Brixen, Kim; Russo, Luis; Claessens, Frank; Papanastasiou, Philemon; Antunez, Oscar; Su, Guoqin; Bucci-Rechtweg, Christina; Hruska, Josef; Incera, Elodie; ... (2012). Fracture risk and zoledronic acid therapy in men with osteoporosis. New England journal of medicine NEJM, 367(18), pp. 1714-23. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa1204061
